placebo-controlled study to evaluate the impact of an anti-TL1A monoclonal antibody in CD. Detailed results are expected to be presented at a scientific forum in 2025. Duvakitug was generally well ...

Eli Lilly and Company LLY announced that the FDA has granted approval to its drug, Omvoh (mirikizumab), for its second ...

Tulisokibart, a TNF–like cytokine 1A monoclonal antibody, has demonstrated significant potential in inducing clinical remission in patients with ulcerative colitis. Read now.

targeting TL1A with duvakitug may mitigate the over-active immune response in these conditions. Duvakitug is currently in a phase 2b clinical study for the treatment of UC and CD, the two most ...

Sanofi SNY and partner Teva Pharmaceuticals TEVA announced positive data from the phase IIb RELIEVE UCCD study on their investigational anti-TL1A ... Ulcerative Colitis (UC) and Crohn's disease ...

Sanofi and Teva Pharmaceuticals have reported that the Phase IIb RELIEVE UCCD study of the human IgG1-λ2 monoclonal antibody targeting TL1A ... ulcerative colitis (UC) and Crohn’s disease (CD ...

Primary endpoint results in UC and CD for high dose represent the highest achieved with any TL1A monoclonal antibody Sanofi and Teva plan to initiate phase 3 development in IBD, pending regulatory ...